Follow by Email

Tuesday, December 6, 2011

Macklin Medical Mission - Cancer Cure

Macklin Medical Mission
Cancer Cure

A number of people have written to us in regards to the above captioned program and have asked us to post a message on Youtube in regards to the cancer cure now undergoing the required multi-layered clinical trials which will take a number of years to complete. The initial trail has now been done and we invite you to view it on Youtube, which includes one of the research flow charts as to how this process generally works. The clinic, for a very small number of a lucky few is now in progress.

While cancer has plagued mankind ever since his debut on planet earth along with those mammals that walked the earth before him, the scourge of cancer has been haunting us ever since. Radiology in its many forms started with the advent of x-rays in the mid 1880’s and chemotherapy, again in its many forms with various cocktails started in the mid 1940’s all of which are very toxic to the human body especially the very young and the very old.

For years those who specialize in the bio-molecular field have studied the body’s autoimmune system and the white blood cells in conjunction with the mechanics of vaccines to recognize and deal with deadly viruses before they invade the human body. For cancer in its three major categories affecting the derma, the blood system and internal organs, getting the white blood cells to recognize the cancer cells as either an invasive cell or a rogue cell that permeates the body is the last frontier in the fight against cancer.

As of April 2011, that frontier has been crossed in grand scale and we now have a cancer cure without the horrific affects of surgery, radiology such as TCI scans with 400 times the radiation of an x-ray and chemotherapy and its wide range of concoctions most of which have side effects, which are worse than the cure itself. All of these now belong in a museum.

Reflecting back on some of our previous Blogs, it is safe to say that 90% of the funds raised in Canada have gone to capital assets [buildings], followed by prizes necessary to attract support in the first place, and followed by [in our opinion] huge and excessive salaries to both administrators and lab technicians alike. Last but not least are of course the patients both young and old. What we did not post on Youtube are the ubiquitous and endless charts for those cancer victims and their mortality rates.

Our primary concern, is and always will be the children and our new Children’s Oncology Group within the Macklin Medical Mission. The cancer cure is here, but in order to get past all the clinical studies and regulatory approvals it will take at least four to five years to get this into the hands of the general practitioners and hence into the public domain to treat patients both young and old and those in the middle.

While we are not looking for hundreds of millions of dollars like that which is raised in Canada every year we are looking for $23 million [a fraction of the amount spent on prizes each year] to build the new Macklin Medical Mission [as seen on the Youtube posting] and to treat our young patients. For them the grand lottery prize is - life itself.

To get us started in this marvellous new program, we have solicited the top fifty companies in Canada including Banks, Trust Companies and Insurance Companies and major manufacturers and will post the results of this program in February of 2012.

However, just as it is in the United States, 95% of all cancer funding comes from individuals just like you and me. There are a number of ways in which you can make a donation to this program at the Macklin Medical Mission sponsored by the Nancy-Griffon Foundation, visit:

1. www.thenancygriffonfund.com and print the donations forms on the web page and mail it to us
2. Or send your draft or money order to the CIBC at 23 Mapleview Dr West in Barrie [Manager]
3. Or send your draft or money order to the TD at 60 Mapleview Dr West in Barrie [Manager]

All personal donations should be by way of a Money Order or a Draft drawn on a Canadian or American bank and the minimum is $100 in order to receive a tax receipt. Corporate donations can be made by way of a corporate cheque. Please include your name and return address.

If you work for a corporation, please ask your company to support this new program. We all know some one who has died from cancer, is dying from cancer or is in the process of receiving treatment for cancer and is undergoing radiation of chemotherapy or both with the possibility of surgery. Its time to stop and look at what the future holds for them and the rest of us. One day, we too may walk in their shoes.

Your choice now is very simple – this is a defining moment - both you the private citizen and the private corporation can decide who and what to fund. The ethics are also simple – choose “inept” or choose “adept”. The larger labs have failed us – thought they can replicate us; the larger cancer raising programs have failed because they failed to finance the smaller labs. It’s the story of the small Dr. Banting lab which discovered insulin so many years ago all over again. But now you know, thankfully to the internet.

This is a private sector initiative. The Government will catch up only when it decides to do so. They are always late to the table. It’s your choice now, whether this takes three years, whether it takes four years, whether it takes five years; and how many more have to die from cancer when they don’t have to. And due to current financial restrictions you will not find this arriving at your front door as a solicitation letter. This is it. Like everything else we do, we are only using modern technology.

Thank you.

Your financial support would be sincerely appreciated. Thank you.

Eric J. Macklin B. Com., FICB, FCSI, FMA, UE
Director
Macklin Medical Mission [Est. 1886]
Chairman
The Nancy-Griffon Foundation Inc [Est. 1975]
Canada
YouTube: Macklin Medical Mission – Cancer Cure

Tuesday, November 15, 2011

Macklin Medical Mission - Stem Cells to Rebuild Hearts (Cancer Research)

Macklin Medical Mission
Cardiac Cells 'heal heart damage'

Stem cells taken from a patient's own heart have, for the first time, been used to repair damaged heart tissue similar to the use of Stem cells from bone marrow to form the basis of a cure for leukemia via white blood cells.
The study, published in the Lancet, in November of 2011 was designed to test the procedure's safety, but also reported improvements in the heart's ability to pump blood. The authors in both cases said the findings were "very encouraging" and are moving on to their second clinical trials.
Level of Improvement
The preliminary trial was on patients with heart failure who were having heart bypass surgery. During the operation, a piece of heart tissue, from the right atrial appendage, was taken.
While the patient was being sewn up, researchers isolated cardiac stem cells from the sample and cultured them until they had about two million stem cells for each patient. The cells were injected about 100 days later.
Doctors measured how efficiently the heart was pumping using the left ventricle ejection fraction - what percentage of blood was leaving one of the heart's main chamber with every beat.
“We believe these finding are very significant” Dr Roberto Bolli University of Louisville
In the 14 patients given the treatment in the first clinical trials, the percentage increased from 30.3% at the beginning of the trial, to 38.5% after four months.
There was no change in the ejection fraction in the seven patients who were not injected with their modified stem cells.
Dr Roberto Bolli, one of the researchers from the University of Louisville, told the BBC: "We believe these finding are very significant.
"Our results indicate that cardiac stem cells can markedly improve the contractile function of the heart."
Heart v Bone Marrow Stem Cells
The heart is not the only source of potentially useful stem cells. Trials have already taken place using stems cells from bone marrow.
Prof Anthony Mathur, from Barts and the London School of Medicine and Dentistry, and Prof John Martin, from University College London, are already conducting large randomised clinical trials.
They are investigating the effect of giving patients stem cells from their own bone marrow, in NHS hospitals, within six hours of a heart attack.
Prof Mathur said of the cardiac stem cell study: "Caveats very much apply. It's a phase one trial so while the early results are great and promising, they need to design a big study to see if the results translate."
He also cautioned that improvements in ejection fraction were not the same as increasing survival or quality of life.
Prof Martin said he was "concerned" that the seven patients in the control group showed no improvement in ejection fraction, which would normally be expected, and that they were not given a sham treatment to account for the placebo effect.
He said that was acceptable when just testing a procedure's safety, but not when looking at effectiveness, which relies on the difference between the treated and control groups.
Prof Peter Weissberg, medical director at the British Heart Foundation, argued that the improvement in heart function was similar to those in other studies.
"This is positive, but the crucial next steps are to see whether this improvement is confirmed in the final completed trial, and to understand whether the cells are actually replacing damaged heart cells or are secreting molecules that are helping to heal the heart," he added.
Dr Bolli argues that stem cells from the heart might be more useful as "their natural function is to replace the cells that continuously die in the heart due to wear and tear".
He plans to start the next phase of clinical trials in 2012.

This is similar in many ways to the use of Stem cells in cancer research which are used to modify or “translate” white blood cells, again taken from the patient, along with using the structural interface with other viruses such as those from the HIV virus which attack cellular structures in the body using the similar attack methods of cancer which “hitch” themselves to live cells. This “hitch interface” is then used to “translate” the body’s white blood cells and give them an “introduction to” the interface of cancer cells which they lacked up until April of 2011.

From here the “translated white blood cells” through the use of Stem cells now become a “naturalized” killer of cancer cells and cancerous tumours in the body. So far leukemia and leukomites and the tumours they create can now be destroyed without any damage to the body’s adjoining tissues. Recover time is now a fraction of what is with the use of the 75 year old chemically based treatments in chemotherapy and the nearly 135 year old use of x-ray based treatments called radiology from the mid 1880’s in all its varied forms.

We, at the Macklin Medical Mission, ask for your financial assistance to support our expanding efforts in this exciting new field of Stem Cell oncology research supported by the Nancy-Griffon Foundation Inc of Canada.

We, at the Macklin Medical Mission, the oldest medical mission in the world, ask for your financial assistance to support our expanding efforts in this exciting new and highly successful field of white blood cells combined with T-Cell oncology research supported by the Nancy-Griffon Foundation Inc of Canada.
So, donate, support and invest in our cancer research – save a life.

Thank you.

Eric J. Macklin B.Com., FICB, FCSI, FMA, UE
Macklin Medical Mission [Est 1886]
Chairman
The Nancy-Griffon Foundation Inc [Est 1975]
Canada

Thursday, October 13, 2011

Macklin Medical Mission - Nanotechnology

Macklin Medical Mission
Nanotechnology – Next Steps

Nanobiotic white blood cells – microbivores
Nanotechnology will also create programmable white blood cells. These nanobiotic white blood cells (‘‘microbivores’’) will patrol the bloodstream, seeking out and destroying undesirable bacteria, viruses and other pathogens.
These nanobots will download software from the Internet for particular problems, and could be programmed to recognize and destroy cancer cells before they would have a chance to grow and spread.40 Won’t it be nice to have some programmable white blood cells in your blood stream to defend against the possibility of biological warfare attack? It would be a simple matter to realize the organism that had been released and your microbivores would immediately download the appropriate program from the Internet to destroy that pathogen. So programmable microbivores will be the ultimate defence against biological weapons of mass distraction or biological warfare agents, as well as against any influenza pandemic or other potential pathogen.
According to Harvey Mackey, 61 percent of famous people didn’t achieve their most noble achievements until after 60 years of age. So, there is a great deal of advantage to remaining in good health until your later decades of life. In the 19th century, Victor Hugo once said ‘‘Forty is the old age of youth, fifty the youth of old age.’’ At the beginning of the 21st century, we can now safely say that 50 or 60 is only the beginning of the second half of life. On December 31, 2004, there were 41 documented ‘‘super centenarians, individuals over 110 years of age.’’41 By the middle of this century, many longevity researchers believe these numbers will increase dramatically.
We have discussed some of the new technologies using “adepts” from Stem cells to reprogram white blood cells to identify and kill cancer cells and tumours now (Bridge One) strategies that we can use to keep our bodies in good health until such time as to when the Biotechnology, a thousand times smaller than white blood cells (Bridge Two) to treat Alzheimer’s and onto Nanotechnology/ AI, ten thousand ties smaller than white blood cells (Bridge Three) revolutions find full expression.
There is no doubt that the 21st century will be worth living to experience especially for those crossing into the second half of their lives. By following the Bridge One strategies that exist today, many people alive today will have the opportunity to see it in its entirety.

We, at the Macklin Medical Mission, the oldest medical mission in the world, ask for your financial assistance to support our expanding efforts in this exciting new and highly successful field of white blood cells combined with T-Cell oncology research supported by the Nancy-Griffon Foundation Inc of Canada.

So, donate, support and invest in our cancer research – save a life.

Thank you.

Eric J. Macklin B.Com., FICB, FCSI, FMA, UE
Macklin Medical Mission [Est 1886]
Chairman
The Nancy-Griffon Foundation Inc [Est 1975]
Canada

Friday, October 7, 2011

Macklin Medical Mission - The Passing of Steve Jobs

Macklin Medical Mission
The Lottery of Lives Lived

Some of the people who work for us also work for Apple Inc and I can’t help but wonder about the lives of so many people who have and those to who continue to have a big impact on our lives. Steve Jobs was one of those and his impact on the lives of others will rank in the millions. He was of course the exception. He grew into childhood then into adulthood and changed the lives and directions not only of the computer, but also of the art world, the film world and the world of animation and of course the lives of everyday folks like you and me.

There are countless lives well lived and lives lived to their fullest measure long before their four score and ten years that is one’s basic and presumed allotment in life. And then there are the lives of children who in the lottery of life we will derive countless new leaders in society who will never get beyond the age of seven. For every one of them there are the countless millions of us who live the life half lived at best.

As Shakespeare once said in his famous play King Lear [3.7:55] where all the world is a stage on the topic of death that “we must endure our going forth even as our coming hence ..”

And on lives lived as Ben Sweetland once said that “We cannot hold a torch to light another's path without brightening that of our own”.

In terms of dealing with cancer while there are those corporate bodies amongst us that raise funds still for the greatly out-moded forms of cancer treatment such as that of radiology dating from the mid 1880’s and now in its varied form - a hundred and thirty years decrepit and relatively unchanged - and that of chemotherapy developed during world war two, it too relatively unchanged, with its many and varied forms of injecting chemicals into the little bodies of children thereby guarantying them a 25% chance of a recurring form of a more deadly form of cancer, combined with their now lowered immune system, a better chance of death …. That perhaps, just perhaps that these people, both private and corporate should consider stepping into the 21st century … away from the 19th century and join with us in dealing with cancer with the bodies own white blood cells combined with “adepts” ... and yes to kill all cancers and tumours …..

How many Steve Jobs and little Emilys of the world do we have to lose before we make the leap into the 21st century, how many board meetings must we deal with before they begin to make the move over to the new treatment ….. and from Psalm 13 “How Long Oh Lord must we wait”

“There are those who can and there are those who can but fail to see” Dr. Lionel A Macklin.

Let us see how long this takes …. those with cancer know how long it won’t take.

We, at the Macklin Medical Mission, the oldest medical mission in the world, ask for your financial assistance to support our expanding efforts in this exciting new and highly successful field of white blood cells combined with T-Cell oncology research supported by the Nancy-Griffon Foundation Inc of Canada.
So, donate, support and invest in our cancer research – save a life.

Thank you.

Eric J. Macklin B.Com., FICB, FCSI, FMA, UE
Macklin Medical Mission [Est 1886]
Chairman
The Nancy-Griffon Foundation Inc [Est 1975]
Canada

Monday, October 3, 2011

Macklin Medical Mission - Cancer Treatment - From the Inept to the Adept

Macklin Medical Mission
Breast Cancer

Breast Cancer Culture
Breast cancer culture, or pink ribbon culture, is the set of activities, attitudes, and values that surround and shape breast cancer in public. The dominant values are selflessness, cheerfulness, unity, and optimism. Appearing to have suffered bravely is the passport into the culture.
The woman with breast cancer is given a cultural template that constrains her emotional and social responses into a socially acceptable discourse: She is to use the emotional trauma of being diagnosed with breast cancer and the suffering of extended treatment to transform herself into a stronger, happier and more sensitive person who is grateful for the opportunity to become a better person. Breast cancer thereby becomes a rite of passage rather than a disease. To fit into this mold, the woman with breast cancer needs to normalize and feminize her appearance, and minimize the disruption that her health issues cause anyone else. Anger, sadness and negativity must be silenced.
As with most cultural models, people who conform to the model are given social status, in this case as cancer survivors. Women who reject the model are shunned, punished and shamed.
The culture is criticized for treating adult women like little girls, as evidenced by "baby" toys such as pink teddy bears given to adult women.
The primary purposes or goals of breast cancer culture are to maintain breast cancer's dominance as the preƫminent women's health issue, to promote the appearance that society is "doing something" effective about breast cancer, and to sustain and expand the social, political, and financial power of breast cancer activists.
Overemphasis
Compared to other diseases or other cancers, breast cancer receives a disproportionate share of resources and attention. In 2001 MP Ian Gibson, chairman of the House of Commons, England all party group on cancer stated "The treatment has been skewed by the lobbying, there is no doubt about that. Breast cancer sufferers get better treatment in terms of bed spaces, facilities and doctors and nurses." Breast cancer also receives significantly more media coverage than other, equally prevalent cancers, with a study by Prostate Coalition showing 2.6 breast cancer stories for each one covering cancer of the prostate. Its no different in Canada. Ultimately there is a concern that favoring sufferers of breast cancer with disproporionate funding and research on their behalf may well be costing lives elsewhere. Partly because of its relatively high prevalence and long-term survival rates, research is biased towards breast cancer. Some subjects, such as cancer related fatique, have been studied in little except women with breast cancer.
One result of breast cancer's high visibility is that most women significantly overestimate their personal risk of dying from it. Misleading statistics, such as the claim that one in eight women will be diagnosed with breast cancer during their lives—a claim that depends on the patently unrealistic assumption that no woman will die of any other disease before the age of 95 obscure the reality, which is that about ten times as many women will die from heart disease or stroke than from breast cancer.
The emphasis on breast cancer screening may be harming women by subjecting them to unnecessary radiation, biopsies, and surgery. One-third of diagnosed breast cancers might recede on their own. Screening mammography efficiently finds non-life-threatening, asymptomatic breast cancers and pre-cancers, even while overlooking serious cancers.
According to H. Gilbert Welch of the Dartmouth Institute for Health Policy and Clinical Practice, research on screening mammography has taken the "brain-dead approach that says the best test is the one that finds the most cancers" rather than the one that finds dangerous cancers, which is essentially the same out-dated approach we found when radiology started back in the mid 1880’s in Peoria Illinois where is was stared. After 120 years nothing has changed.
Prognosis
A prognosis is a prediction of outcome and the probability of progression-free survival (PFS) or disease-free survival (DFS). These predictions are based on experience with breast cancer patients with similar classification. A prognosis is an estimate, as patients with the same classification will survive a different amount of time, and classifications are not always precise.
Survival is usually calculated as an average number of months (or years) that 50% of patients survive, or the percentage of patients that are alive after 1, 5, 15, and 20 years. Prognosis is important for treatment decisions because patients with a good prognosis are usually offered less invasive treatments, such as lumpectomy and radiation or hormone therapy, while patients with poor prognosis are usually offered more aggressive treatment, such as more extensive mastectomy and one or more chemotherapy drugs.
In Canada one in eight women will be diagnosed with breast cancer and half of those diagnosed will die within five years either after the initial bout of cancer or from the re-occurence of a more malignant form of cancer due to the highly aggressive forms of cancer treatment from radiology or its more designer form of radiology called MRI or chemotherapy with its multifarious list of designer drugs and chemicals all part of and industry wide level of inept laboratories and their forms of “triage”.
Its clearly time to go from the “inept” to the “adept” and jump into the 21st century. Its time to grow up!
Prognostic factors are reflected in the classification scheme for breast cancer including stage, (i.e., tumor size, location, whether disease has spread to lymph nodes and other parts of the body), grade, recurrence of the disease, and the age and health of the patient.
The stage of the breast cancer is the most important component of traditional classification methods of breast cancer, because it has a greater effect on the prognosis than the other considerations. Staging takes into consideration size, local involvement, lymph node status and whether metastatic disease is present. The higher the stage at diagnosis, the poorer the prognosis. The stage is raised by the invasiveness of disease to lymph nodes, chest wall, skin or beyond, and the aggressiveness of the cancer cells. The stage is lowered by the presence of cancer-free zones and close-to-normal cell behaviour (grading). Size is not a factor in staging unless the cancer is invasive. For example, Ductal Carcinoma In Situ (DCIS) involving the entire breast will still be stage zero and consequently an excellent prognosis with a 10yr disease free survival of about 98%.
The breast cancer grade is assessed by comparison of the breast cancer cells to normal breast cells. The closer to normal the cancer cells are, the slower their growth and the better the prognosis. If cells are not well differentiated, they will appear immature, will divide more rapidly, and will tend to spread. Well differentiated is given a grade of 1, moderate is grade 2, while poor or undifferentiated is given a higher grade of 3 or 4 (depending upon the scale used). The most widely used grading system is the Nottingham scheme; details are provided in the discussion of breast cancer grade..
The presence of estrogen and progesterone receptors in the cancer cell is important in guiding treatment. Those who do not test positive for these specific receptors will not be able to respond to hormone therapy, and this can affect their chance of survival depending upon what treatment options remain, the exact type of the cancer, and how advanced the disease is.
In addition to hormone receptors, there are other cell surface proteins that may affect prognosis and treatment. HER2 status directs the course of treatment. Patients whose cancer cells are positive for HER2 have more aggressive disease and may be treated with the 'targeted therapy', trastuzumab (Herceptin), a monoclonal antibody that targets this protein and improves the prognosis significantly.
Younger women tend to have a poorer prognosis than post-menopausal women due to several factors. Their breasts are active with their cycles, they may be nursing infants, and may be unaware of changes in their breasts. Therefore, younger women are usually at a more advanced stage when diagnosed. There may also be biologic factors contributing to a higher risk of disease recurrence for younger women with breast cancer.
United States and Canada
The lifetime risk for breast cancer in Canada is usually given as about 1 in 8 (12%) of women by age 95, with a 1 in 35 (3%) chance of dying from breast cancer. Sadly its “only” 1 in 12 in the United States. Clearly with the aging popluations in both countries Canada is falling behind due to the inept nature of research in Canada. With the nearly half billion being raised in Canada from a number of sources this is a very bad return on their investment.
In reality this is about 5%. This calculation assumes that all women live to at least age 95, except for those who die from breast cancer before age 95. Recent work, using real-world numbers, indicate that the actual risk is probably less than half the theoretical risk.
The United States has the highest annual incidence rates of breast cancer in the world; 128.6 per 100,000 in whites and 112.6 per 100,000 among African Americans. It is the second-most common cancer (after skin cancer) and the second-most common cause of cancer death (after lung cancer). In 2007, breast cancer was expected to cause 40,910 deaths in the US (7% of cancer deaths; almost 2% of all deaths). This figure includes 450-500 annual deaths among men out of 2000 cancer cases.
In the US, both incidence and death rates for breast cancer have been declining in the last few years in Native Americans and Alaskan Natives. Nevertheless, a US study conducted in 2005 indicated that breast cancer remains the most feared disease, even though heart disease is a much more common cause of death among women. Many doctors say that women exaggerate their risk of breast cancer.
There are those who can and do and unfortunately in the “highly funded cancer industry” in both Canada and the United States there are those who can’t and simply don’t know how - and are collecting huge salaries and write-off for equipment with a technology dating from either the mid 1880’s or 1940’s. The recipes and concoctions have changed ever so little but the results are dismal.
After rising for nearly three decades, the mortality due to cancer in its many and varied forms fell in Canada and most of its peer countries in the 1990’s. The number has continued to decrease but not as quickly in Canada and many other countries. In 1997 for example the U.S. and Canada experineced an equal number of deaths due to cancer, at 178 per annum per 100,000 patients reported. But since then the U.S. rate of mortality has since decreased much more quickly than in Canada, which for Canada is indicated in large part to a mis-direction in funding a research effort resulting in a considerable gap between Canada and the U.S. mortality rate. Due to the huge level of funding someone is benefiting but not the patients.
Considering that both the U.S. and Canada have slipped from the top to the 8th and 12th position behind many other smaller countires with considerable less resources and GDP, it clearly indicates again a mis-direction of funding a resources even with an aging population. Cancer is cancer so combined with the highly abrasive nature of radiology and chemotherapy on a middle aged body leaving it open to a recurrence of cancer and older body of patients will simply be left further behind and with fewer options.
Now we have the inept leading the inept within a self regulating “cancer industry”. If one doesn’t like that - then the numbers prove the point. What is – is! And death is still death.
Clearly, what is needed in Canada is a comprehensive and integrated cancer control strategy outside of the control of the “cancer industry” to set and pursue a strategic methodology of promotion, prevention and screening of specific targets to not only get us back on track – while at the same time reviewing new cancer treatments – not just the reworking again and again two very olde sytems as we currently are – buty especially that of stem cell research and working with the body’s own defensive system – the white blood cel;s modified with “adepts” – re-introducing them back into the body in a new highly successful treatment to bring about the necrosis of cancer cells and tumours now under going very successful clincial trials which started in March of 2011 and being monitored by the Macklin Medical Mission in Canada.
Your choice now is very simple – both you the private citizen and the private corporation can decide who and what to fund. The ethics are also simple – choose “inept” or “adept”. Thank you.
This is a private sector initiative. The Government will catch up only when it decides to do so. They are always late to the table.

We, at the Macklin Medical Mission, the oldest medical mission in the world, ask for your financial assistance to support our expanding efforts in this exciting new and highly successful field of white blood cells combined with T-Cell oncology research supported by the Nancy-Griffon Foundation Inc of Canada.
So, donate, support and invest in our cancer research – save a life.

Thank you.


Eric J. Macklin B.Com., FICB, FCSI, FMA, UE
Macklin Medical Mission [Est 1886]
Chairman
The Nancy-Griffon Foundation Inc [Est 1975]
Canada

Friday, September 30, 2011

Macklin Medical Mission - Cancer - The True Story

Macklin Medical Mission
Death Rate due to Cancer
The Real Story


Cancer has been a fact of life in all its forms ever since life began on planet earth and has been one of the major limiters of life in general and why so many died long before they turned 40. In some countries on this planet – remains true to this very day.

A Little History Lesson

1. Radiology
This cancer treatment such as it is actually started in 1896. Interestingly enough this “therapy” turned up ten years after the founding of the Macklin Medical Mission to China in 1886. The treatment was developed by Mr. Arnold Feldman PhD in biochemistry at the department of radiation at the Methodist Medical center at the general hospital in Peoria, Illinois where they experimented with the use of X-Rays to treat cancer. Their initial treatments dealt with skin cancer and from there moved deeper into the body with some horrific side effects from the high energy form of radiation. The abrasive nature of this form of treatment is legendary in all its forms and yet we raise billions of dollars for this hundred year old plus form of cancer treatment. The modern “adjunctive form” of this treatment radiation treatment is now called machine-readable information magnetic resonance imaging or MRI. And while is it is much touted as a cancer treatment, the exposure to the skull has a proven increase in the rate of cancer by 50 percent especially brain cancer. [Again we refer you to Wikipedia to read on the side effects of MRI treatment - “it is still possible to deal with some of the side effects of the MRI treatment” – nice!

2. Chemotherapy
This cancer therapy if you can call it that is a little newer. This era of cancer chemotherapy began in the 1940’s [seventy years ago] with the first use of nitrogen mustard and folic acid antagonist drugs. This highly abrasive cancer treatments based on chemical based drug therapies development has exploded since then into a multi-billion dollar industry. The “targeted therapy” revolution had arrived, but many of the principles and limitations of chemotherapy discovered by the early researchers back in the 1940’s during the war still apply. The use of chemicals is simply nauseating in all their many forms. It’s as effective then as is it is now – i.e. “not very” [This from Wikipedia in 2011]

3. Mortality Rate due to Cancer in Canada
Again a little history. As he set off on his “Marathon of Hope” in 1980, Canadian icon Terry Fox imagined what could happen if Canadians put their support behind cancer research. Since then, Canada has made great strides in cancer care. But unfortunately maybe we haven’t due to the misdirection of funds raised in Canada.
Cancer is still the leading cause of premature death in Canada. The rising number of Canadians diagnosed with cancer continues to put significant demands on health systems. After al these years, progress on preventing cancer and improving its management is still a somewhat unpredictable process, making it an ongoing health-care challenge for governments at home and abroad. This should no longer be the case.
The impact that cancer has on the lives of patients especially the young, their families, and the health-care system cannot begin to be overstated. The long-term emotional, physical, and psychological strain on individuals diagnosed with cancer—and their families—is as tragic as it is profound. Just about everyone in Canada has been touched by cancer in some way.
Even today, one in four Canadians will die of cancer, with a slightly higher risk among men than among women and tragically the highest risk being to the children. In 2009-10, an estimated 171,000 Canadians will be diagnosed and 75,300, roughly half will die of cancer — an increase of 4,600 newly diagnosed cases and 1,500 deaths from the year before.
We aren’t moving ahead we are moving backwards due to outdated technology and treatments are largely to blame. The treatment of cancer is an industry in Canada and the vested interests of many in it is also largely to blame considering the salaries and the perks and the “prizes” and the consultants. Yes we are moving backwards the children who should be living are dying because of it and because of a lack of vision.
The cost of cancer care also places a heavy burden on the health-care system. One estimate finds that over the next 30 years beginning in 2012, 2.4 million workers will get cancer and 872,000 will die from the disease. Meanwhile, cancer will cost the Canadian economy an estimated $177.5 billion in direct health-care costs, $199 billion in corporate profits, $250 billion in taxation revenues, and $543 billion in wage-based productivity.
Cancer continues to exact a huge toll on the lives of Canadians; the country must not lag behind its peer countries in its efforts to reduce the incidence and mortality of cancer.
Canada is not a leader – it is a follower and a far distant follower at that – we stand 12th in all the western counties – that is absolutely disgusting and says a lot about the medical fraternity in Canada. Try telling that to your family physician and watch his or her face – then tell that to parents of children as they watch their children die in their arms, as Sunnybrook, Toronto Sick Kids, Mount Sinai and on it goes – its is truly nauseating in the extreme.

Canada gets a “B-” grade and ranks 12th among 16 peer countries. (Recent data are not available for Belgium.) In 2004—the most recent year of published data for Canada—there were 169 deaths due to cancer per 100,000 population. That rate rose – yes rose to an estimated 166 deaths per 100,000 population in 2006-7. That is absolutely pathetic.
The top performer — Finland a fraction of the Canadian GDP — had 135 deaths per 100,000 due to cancer; while the worst performer — Denmark — had 199 people die of cancer for every 100,000 population.
The Canadian Cancer Society reported recently that cancer will continue to place an increasing burden on Canadian society. Although the cancer mortality rate has dropped, the number of new cancer cases and deaths attributed to cancer actually continues to rise steadily as the Canadian population grows and ages.
Although some of the risks that lead to some cancers are very well documented, other cancers (and their related risk factors – spread ) continue to be something of a mystery. Whatever the current state of research and general knowledge, Canadians need to make the link between behaviours — such as poor eating habits, weight control, inactivity, alcohol, and tobacco consumption — and cancer. Most importantly, they need to adjust their lifestyles to reduce risks.

Even more importantly, Canadians need to make the link between behaviours of those raising funds for cancer research and where all the money is going. After all these years as I have said before cancer research is an “industry onto itself with vested interests in staff and outdated machines and outdated treatments – all of this would collapse if a cure was actually found and proven in clinical trials.

At one time it was heresy to say the world was round or that blood flowed in the human body or that he sun was the center of the galaxy - well the cure for cancer has arrived and it arrived in April of 2011 and using “adepts” from T-Cells combined through translational therapy in the lab with white blood cells and given them the cancer “codex” – all cancer can be treated at what ever stage and yes “cured” – without side effects and without any invasive treatments and yes without surgery.

The Macklin Medical Mission – Children’s Oncology Group [COG] is just the first and will be the only center in Canada to bring this treatment to Canadians once the trials are finished and once it has been approved by the Federal Government of the United States and Canada.

To do that we need to raise $23 million to build the oncology center – and to put an end to all those outdated cancer treatments which belong in the Rue Morgue or Madame Toussaud’s Wax Museum. The center will take a few years but it will be well worth it. Just ask the children who are dying still by the thousands. Better still ask their parents.

In our next Blog we will list all those corporations in Canada who refuse to help and who are tied to the existing forms of cancer treatment through their executive networks.

When the Macklin Medical Mission does become a reality- remember you first heard about while blood translational cellular cancer therapy from us. The “me-too” syndrome will quickly become apparent to coin a phrase all too soon by those using radiology and chemotherapy – after all they have a huge monolithic industry to preserve and staff to maintain – as usual.

12th place eh! …. Its time to be first! For the children, I say those who are last shall be first- and those who are first at the money trough shall be last.

One last thing … while Canadian doctors will want to know about this treatment, they will be among the very the last to support this new treatment financially.

We, at the Macklin Medical Mission, the oldest medical mission in the world, ask for your financial assistance to support our expanding efforts in this exciting new and highly successful field of white blood cells combined with T-Cell oncology research supported by the Nancy-Griffon Foundation Inc of Canada.
So, donate, support and invest in our cancer research – save a life.

Thank you.


Eric J. Macklin B.Com., FICB, FCSI, FMA, UE
Macklin Medical Mission [Est 1886]
Chairman
The Nancy-Griffon Foundation Inc [Est 1975]
Canada

Saturday, September 24, 2011

Macklin Medical Mission - Children's Oncology Centre (COG)

Annual Death Rate of Children Dying from Cancer
1975 to 2010

Remember – Remission is not a cure

What are the most common types of childhood cancer?

Among the 12 major types of childhood cancers, leukemias (blood cell cancers) and cancers of the brain and central nervous system account for more than half of the new cases. About one-third of childhood cancers are leukemias. The most common type of leukemia in children is acute lymphoblastic leukemia. The most common solid tumors are brain tumors (e.g., gliomas and medulloblastomas), with other solid tumors (e.g., neuroblastomas, Wilms tumors, and sarcomas such as rhabdomyosarcoma and osteosarcoma) being less common.

How many children are diagnosed with cancer in Canada and the United States annually?

In the United States in 2007, approximately 10,400 children under age 15 were diagnosed with cancer and about 1,545 children will die from the disease (1). Although this makes cancer the leading cause of death by disease among U.S. children 1 to 14 years of age, cancer is still relatively rare in this age group. On average, 1 to 2 children develop the disease each year for every 10,000 children in the United States and Canada.

How have childhood cancer incidence and survival rates changed over the years?

Over the past 20 years, there has been some increase in the incidence of children diagnosed with all forms of invasive cancer, from 11.5 cases per 100,000 children in 1975 to 14.8 per 100,000 children in 2004 to 16.9 in 2011. During this same time, however, death rates declined dramatically and 5-year survival rates increased for most childhood cancers. For example, the 5-year survival rates for all childhood cancers combined increased from 58.1 percent in 1975–77 to 79.6 percent in 1996–2003 (2). This improvement in survival rates is due to significant advances in treatment, resulting in a cure or long-term remission for a substantial proportion of children with cancer with the use of chemo or radiology which unfortunately has a 25% chance of some form of recurring cancer which drops the over all survival rate to 51.8%.

Long-term trends in incidence for leukemias and brain tumors, the most common childhood cancers, show patterns that are somewhat different from the others. Incidence of childhood leukemias appeared to rise in the early 1980s, with rates increasing from 3.3 cases per 100,000 in 1975 to 4.6 cases per 100,000 in 1985. Rates in the succeeding years have shown no consistent upward or downward trend and have ranged from 3.7 to 4.9 cases per 100,000.

For childhood brain tumors, the overall incidence rose from 1975 through 2009, from 2.3 to 3.2 cases per 100,000 (2), with the greatest increase occurring only from 1983 through l986.

An article in the September 2, 1998, issue of the Journal of the National Cancer Institute suggests that the rise in incidence from 1983 through 1986 may not have represented a true increase in the number of cases, but may have reflected new forms of imaging equipment (magnetic resonance imaging or MRI) that enabled visualization of brain tumors that could not be easily visualized with older equipment (3). Other important developments during this time period included the changing classification of brain tumors, which resulted in tumors previously designated as “benign” being reclassified as “malignant,” and improvements in neurosurgical techniques for biopsying brain tumors. Regardless of the explanation for the increase in incidence that occurred from 1983 to 1986, childhood brain tumor incidence has been essentially stable since the mid-1980s.

A monograph based on data from the National Cancer Institute’s (NCI) Surveillance, Epidemiology, and End Results (SEER) Program was published in 1999 on U.S. trends in incidence, mortality, and survival rates of childhood cancers. This monograph, Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975–1995, is available at http://seer.cancer.gov/publications/childhood/ on the Internet. In 2006, SEER published another monograph, Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975–2000. This monograph is the first to collect detailed information about cancer incidence and outcomes in adolescents and young adults (AYA). It provides population-based incidence, mortality, and survival data specific to cancers that occur in the AYA population, along with epidemiological data and risk factors for the development of age-specific cancers. This resource is available at http://seer.cancer.gov/publications/aya/ on the Internet. More recent cancer statistics for children ages 0–14 and 0–19 are available in sections 28 and 29 of the SEER Cancer Statistics Review, 1975–2004 at http://seer.cancer.gov/csr/1975_2004/ on the Internet.

What are the known or suspected causes of childhood cancer?

The causes of childhood cancers are largely unknown. [This is blatantly not true] But the cure for all cancers is known as of April 2011. So why not fund it and use it rather than simply watch more children die.

Environmental causes of childhood cancer have long been suspected by many scientists but have been difficult to pin down, partly because cancer in children is rare and because it is difficult to identify past exposure levels in children, particularly during potentially important periods such as pregnancy or even prior to conception. In addition, each of the distinctive types of childhood cancers develops differently—with a potentially wide variety of causes and a unique clinical course in terms of age, race, gender, and many other factors. Possible risk factors for specific childhood cancers are discussed in the SEER monograph mentioned above. It can be found at http://seer.cancer.gov/publications/childhood/ on the Internet.

A number of studies are examining suspected or possible risk factors for childhood cancers, including early-life exposures to infectious agents; parental, fetal, or childhood exposures to environmental toxins such as pesticides, solvents, or other household chemicals; parental occupational exposures to radiation or chemicals; parental medical conditions during pregnancy or before conception; maternal diet during pregnancy; early postnatal feeding patterns and diet; and maternal reproductive history

What have studies shown about the possible causes of childhood cancer?

For several decades, the NCI, a part of the National Institutes of Health (NIH), has supported national and international collaborations devoted to studying the causes of cancer in children. Key findings from this research include the following:
High levels of ionizing radiation from accidents or from radiotherapy have been linked with increased risk of some childhood cancers.

Children with cancer treated with chemotherapy and/or radiation therapy are at an increased risk of 25% for developing a second primary cancer. For example, certain types of chemotherapy, including alkylating agents or topoisomerase II inhibitors (e.g., epipodophyllotoxins), can and will cause an increased risk of leukemia. That is a terrible price for young children and their parents to pay. It just prolongs the process of “inhumanization”. But there is a cure for cancer now.

Recent research has shown that children with AIDS (acquired immunodeficiency syndrome), like adults with AIDS, have an increased risk of developing certain cancers, predominantly non-Hodgkin lymphoma and Kaposi sarcoma. These children also have an additional risk of developing leiomyosarcoma (a type of muscle cancer).

Certain genetic syndromes (e.g., Li-Fraumeni syndrome, neurofibromatosis, and Gorlin syndrome) have been linked to an increased risk of specific childhood cancers. Children with Down syndrome have an increased risk of developing leukemia.
Low levels of radiation exposure from indoor radon have not been significantly associated with childhood leukemias.
Ultrasound use during pregnancy has not been linked with childhood cancer in numerous large studies.
Residential magnetic field exposure from power lines has not been significantly associated with childhood leukemias.
Pesticides have been suspected to be involved in the development of certain forms of childhood cancer based on interview data. However, interview results have been inconsistent and have not yet been validated by physical evidence of pesticides in the child’s body or environment.
No consistent findings have been observed linking specific occupational exposures of parents to the development of childhood cancers.
Several studies have found no link between maternal cigarette smoking before pregnancy and childhood cancers, but increased risks have been related to the father’s smoking habits in studies in the United Kingdom and China.
Little evidence has been found to link specific viruses or other infectious agents to the development of most types of childhood cancers, though investigators worldwide are exploring the role of exposures of very young children to some common infectious agents that may protect children from, or put them at risk for, developing certain leukemias.
What research is NCI currently doing on childhood cancer?

The NCI is funding a large portfolio of studies (http://fundedresearch.cancer.gov/) looking at the causes of and the most effective treatments for childhood cancers. Ongoing investigations include:
Studies to identify causes of the cancers that develop in children: The Children’s Oncology Group (COG) (http://www.childrensoncologygroup.org) is evaluating potential risk factors for a variety of childhood cancers. Very large studies have been completed of childhood acute lymphoblastic leukemia, acute myeloid leukemia, non-Hodgkin lymphoma, primitive neuroectodermal tumors of the brain, astrocytoma, neuroblastoma, and germ cell tumors. One large study, the Childhood Cancer Survivor Study, is evaluating the risks of second cancers related to radiation therapy and chemotherapy received by survivors of childhood cancer as part of treatment for their primary cancer (see below).

COG has also established a Childhood Cancer Research Network that creates a national registry of children with cancer. This initiative builds upon the unique NCI-supported national clinical trials system for treating children with cancer.

Monitoring of U.S. and international trends in incidence and mortality rates for childhood cancers: By identifying places where high or low cancer rates occur, researchers can uncover patterns of cancer that provide important clues for further in-depth studies into the causes and control of cancer.

Studies to better understand the biology of childhood cancer, with the hope that this understanding will lead to new treatment approaches that target critical cellular processes required for cancer cell growth and survival: The Childhood Cancer Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative was established by the NCI and the Foundation for the National Institutes of Health to identify and validate therapeutic targets in childhood cancers. The first TARGET project focuses on targets for high-risk acute lymphoblastic leukemia and the second TARGET project focuses on neuroblastoma. More information about the TARGET Initiative can be found in the article “Initiative TARGETs Childhood Cancer” at http://www.cancer.gov/NCICancerBulletin/NCI_Cancer_Bulletin_112106 on the Internet.

The Fund Raising for Cancer Research is a $25 billion dollar a year Corporate Drug Culture

Preclinical studies (animal studies) of new agents to identify promising anticancer drugs that can be evaluated in clinical trials: The NCI-supported Pediatric Preclinical Testing Program (PPTP) systematically evaluates new drugs and substances using animal models (animals with a cancer similar to or the same as a cancer found in children) to find the drugs most likely to have significant anticancer effects in clinical trials. The program is based on a large amount of research showing that animal models imitate the effects of proven anticancer drugs and can be used to prospectively identify new drugs that are effective against childhood cancers in subsequent patient studies. More information about the PPTP is available at http://pptp.nchresearch.org/ on the Internet. Questions concerning the PPTP can be addressed to the PPTP Project Officer, Dr. Malcolm Smith (malcolm.smith@nih.gov).

Projects designed to improve the health status of survivors of childhood cancers: The NCI funds the Childhood Cancer Survivor Study (CCSS), a study coordinated by St. Jude Children’s Research Hospital. The CCSS has over 25 sites across the country at medical institutions with doctors specializing in long-term care for children and young adults. This study was created to gain new knowledge and to educate cancer survivors about the long-term effects of cancer and cancer treatment. Information about the study is available at http://ccss.stjude.org/ on the Internet.
Clinical trials to identify superior treatments for childhood cancers, thereby leading to improved survival rates for children with cancer: Each year about 4,000 children enter 1 of approximately 100 ongoing clinical trials sponsored by the NCI. The following groups are conducting these trials:

The COG, with support from the NCI, conducts clinical trials devoted exclusively to children and adolescents with cancer at more than 200 member institutions, including cancer centers of all major universities, teaching hospitals throughout the United States and Canada, and sites in Europe and Australia. COG was formed in 2000 by the merger of four children’s cancer cooperative groups to accelerate the search for a cure for childhood cancers and to make it possible for children with cancer, regardless of where they live, to have access to state-of-the-art therapies and the collective expertise of world-renowned pediatric specialists.

The Pediatric Brain Tumor Consortium (PBTC) (http://www.pbtc.org) includes 10 leading academic institutions with extensive experience in the design and conduct of clinical trials for children with brain tumors. The group’s primary objective is to rapidly conduct phase I and II clinical evaluations of new therapeutic drugs, treatment delivery technologies, new biological therapies, and radiation treatment strategies in children up to age 21 with primary central nervous system (CNS) tumors. Another objective of the PBTC is to develop and coordinate innovative neuroimaging techniques. Results from PBTC studies are made available to large international collaborative groups for confirmatory phase II and multiagent phase III clinical trials.

New Approaches to Neuroblastoma Therapy (NANT) (http://www.nant.org) is a consortium of university and children’s hospitals funded by the NCI to test promising new therapies for neuroblastoma. NANT members constitute a group of closely collaborating investigators linked with laboratory programs where novel therapies for high-risk neuroblastoma are being developed. The group conducts early clinical trials to test new drugs and new combinations of drugs so promising therapies can be tested nationally.

The Pediatric Oncology Branch (POB) (http://pediatrics.cancer.gov) of the NCI’s Center for Cancer Research conducts basic, preclinical, and clinical studies of childhood cancer at the NIH Clinical Center in Bethesda, MD. Basic studies include analyses of genetic and biological characteristics of childhood cancers, as well as the study of immune system interactions with these cancers and the effects of chemotherapy on the immune system. Preclinical studies by the POB identify new drugs and types of immunotherapy (treatment to boost the immune system’s ability to fight cancer), as well as agents to control infectious diseases that occur in childhood cancer patients. An active clinical trial program includes phase I and phase II studies of new agents to treat childhood cancers, with a focus on molecularly targeted therapy and immunotherapy, as well as bone marrow transplantation and the development of immunotoxins (antibodies linked to a toxic substance that bind to cancer cells and kill them) to treat childhood leukemia. The POB also develops and tests new treatments for tumors associated with genetic predisposition syndromes such as neurofibromatosis type 1 and multiple endocrine neoplasia.

Evaluations of new drugs that may be more effective against childhood cancers and that may have less toxicity for children: The COG Phase I/Pilot Consortium is a major component of the NCI’s pediatric drug development program. The primary objective of the consortium is to develop and implement pediatric phase I and pilot studies to promote the integration of advances in cancer biology and therapy into the treatment of childhood cancer. The consortium includes approximately 20 institutions that carefully monitor the drugs for toxicity and safety. After their initial evaluation for safety in children by the consortium, the agents and regimens can then be studied within the larger group of COG institutions to determine their role in the treatment of specific childhood cancers.

Summary: The Macklin Medical Mission – There is an answer

There isn’t a single mention here of the very new and highly successful clinical trials being run using “translational white blood cells” from the cancer patients own body for a non-drug non-chemical non-invasive based cancer treatment for the cure of all forms of paediatric cancers with the Children’s Oncology Center to be build and established at the Macklin Medical Mission [COG] once the clinical trials are finished and both Federal Approval and Federal matching funding is available.

The longer it takes, the longer we will watch and read about children dying in the arms of their parents.

We, at the Macklin Medical Mission, the oldest medical mission in the world, ask for your financial assistance to support our expanding efforts in this exciting new and highly successful field of white blood cells combined with T-Cell oncology research supported by the Nancy-Griffon Foundation Inc of Canada.
So, donate, support and invest in our cancer research – save a life.

Thank you.


Eric J. Macklin B.Com., FICB, FCSI, FMA, UE
Macklin Medical Mission [Est 1886]
Chairman
The Nancy-Griffon Foundation Inc
Canada

Thursday, September 8, 2011

Macklin Medical Mission - New Children's Cancer Treatment Center (COG)

Cancer Research & Treatment

“ What lies ahead in our powers to do,
Also lies ahead in our powers not to do. “ – Dr. Lionel A. Macklin
School of Medicine
Cody Medal 1927
University of Toronto

For this Blog on the Macklin Medical Mission and its efforts to raise the $23 million in funds for the new cellular treatment center, we would like to address a couple of issues relevant to all those about to be afflicted with cancer, those currently dealing with many of the various cancers and those who have been “cured” with either radiology and chemotherapy. For those in the last group, they have according to 2011 statistics a 25% chance of a recurring form of cancer simply due to the extremely abrasive and toxic nature of radiology and chemotherapy.

The time has most definitely come to bring cancer research not only into the 21st century but to focus on the end game of cancer research itself. It’s not that we are researching the cure for specific cancers but for the cancer cell itself. I think we can all agree to that simple fact.

But the simple fact is that so many who are involved in either raising funds for cancer research per say or in doing cancer research into a specific affliction of cancer is that it is for the most part emotionally driven. Let me put it this way. Someone dies, which is usually the case, of say lung cancer, or breast cancer, or ovarian cancer, or prostate cancer and off they go to start a foundation to raise funds for that particular form of cancer and in so doing lose sight of the fact that cancer is cancer.

The amount of money raised by all these groups in fighting cancer for their chosen field of endeavour is gargantuan – for North America along is amounts to $3.5 billion dollars from both the private and public sector including of course Government funding. So there we have it $3.5 billion and growing. Of that amount almost 80% is spent on fund raising activities including prizes and the outrageous some of money for staff and doctors and nurses and councillors. In other words it is an industry onto itself. It promises much and delivers little in terms of the success ratio of the living and the dying.

To prove a point again, I refer you to the National Cancer Research Council on statistics in England, the United States and Canada. It is practically the same the world over. To date, and at best folks with cancer can expect an approximate survival rate of about 60% on a combined basis of all cancers. With radiology and chemotherapy this 60% has a 25% chance of remission, as I have said due in large part to the abrasive and harsh reality that it delivers to the autoimmune system of the body. Terrific. So that reduces the 60% to – let see 60 minus 25% … that’s only 45%.

After all these years and $3.5 in annual funding; who are we kidding other than ourselves and the kids for whom we treasure the most.

OK now, let us move into the 21st century.

We all now about vaccinations against the common cold right. Pretty simple stuff when you thing about it. Actually the common cold was not all that simple 50 years ago. People were dying by the 100’s of thousands. What we did was to develop a vaccine and have the annual vaccination of millions of folks starting with the most vulnerable, that’s right - the kids. The concept was developed in a small laboratory in a small Canadian town on shoe-string budget. Same story with antibiotics, another small laboratory; and again with the treatment of diabetes with insulin – Dr. Banting in a small laboratory in Alliston. Well known to Dr. Lionel Macklin. Along with Dr. Evan Shoute of London who developed vitamin E. All from the University of Toronto and all with small labs and all in small towns working back and forth with the University of Toronto. Also well known in the United States for their work.

So the next time you buy a few tickets to one of many well promoted cancer fund raising corporation like Sunnybrook for instance and think of the mansions in Oakville, that grand cottage and the fancy cars that require $20,000 in annual insurance fees to run should you be so lucky to win one – think of another laboratory that has not lost sight of the cancer cell itself. After all it is the necrosis of the cancer cell we all want. Charging off into the wild blue yonder for the cure of cancer this and cancer that is a waste of assets, funding and effort.

Back to thinking of vaccinations, and how it works, - we develop the strain we want to “cure” for the year and develop a vaccine, purify it and sell it buy the $100’s of millions to labs and governments around the world each year. Inject it into the shoulder muscle and then the white cells pick it up initially as an intruder then – bingo that “ah-ha moment” they interpret it for what it is and go charging off to kill that particular “spectrum of cold virus” in the body. Aren’t white cells neat.

OK – white cells, the army cells of the body. What if we find a cancer victim – that’s awfull, lets change that to “someone with cancer” – say breast cancer, lung cancer, ovarian cancer, brain cancer and withdraw some blood and run it through the ubiquitous centrifuge into red cells, white cells and plasma. Take some of the white cells and with T-cells “translate” a few of these “jacked cells” and re-inject them back into the same body they came out of. These translated cells have been given the “cancer cell interface” that they have never had before [vaccinated if you like] to use a computer term and go hunting for cancer cells. White cells may die in the process but lucky for the programme they multiply – just as God says “go ye forth and multiply”…. And bingo – cancer cell necrosis.

75% of the patients in the first group with stage four cancer had a complete 100% remission with the other 25% a 70% remission. Far in excess of the anticipated results including the growth in white blood cells. For those who were now cancer free these white blood cells now have the “cancer Codex” to kill again. It will never come back.

The clinic is now working with its second group of patients and the anticipated results will be better yet, including that 25% which may simply mean that they needed a second dosage.

If you are so lucky to find this Blog, and if we are so lucky in getting our $23 million in funding, you may be so lucky to find your cancer cure.

It is now up to you the tax payer, your company – another tax payer and its Board of Directors.

Cancer is no lottery ticket my friends, but then maybe we are wrong – buy a ticket instead – but remember this …..

“ What lies ahead in our powers to do,
Also lies ahead in our powers not to do. “

The longer it takes, the longer we will watch and read about children dying in the arms of their parents.

We, at the Macklin Medical Mission, the oldest medical mission in the world, ask for your financial assistance to support our expanding efforts in this exciting new and highly successful field of white blood cells combined with T-Cell oncology research supported by the Nancy-Griffon Foundation Inc of Canada.
So, donate, support and invest in our cancer research – save a life.

Thank you.

Eric J. Macklin B.Com., FICB, FCSI, FMA, UE
Macklin Medical Mission [Est 1886]
Chairman
The Nancy-Griffon Foundation Inc
Canada

Sunday, September 4, 2011

Macklin Medical Mission - New Children's Cancer Treatment

The Macklin Medical Mission
Center for Oncology Research and Treatment
Executive Summary

The Macklin Medical Mission is part of the Nancy-Griffon Foundation dedicated to the medical health and welfare of people. Over the years we have been involved in developing the funding and assistance for missions of medical specialists in the field of paediatrics and their staff and personnel around the world ever since the spring of 1885.

For the most part these team of specialist and generalist have been involved in reconstructive plastic surgery for the eyes, ears, nose and throat and in some cases rhinoplasty for cleft palates. Initially the latter came out of the work of many of our specialist as the result of war injuries, from the Crimean War to both the First and Second World Wars again specializing in injuries to the skull structure as well as those that evolved from birth defects later on.

From the early work led by Dr. William E. Macklin at the Nanking Medical Mission in Nanking China, later Nanjing up to the period of General Chiang Kai-Shek in the mid to late 1880’s to the late 1930’s to Dr. Alfred H. Macklin at the King George V hospital in Dublin Ireland. Both of these two famous Canadian doctors were later joined by Dr. Christine S. Macklin, one of the first women doctors to graduate from the University of Toronto and Dr. Daisy M. Macklin, both of who joined the Toronto Women’s Hospital. Dr. Bertrand Chapman’s work in New Delhi India was another medical mission supported by the Macklin Foundation.

Over the last 125 years Macklin doctors and their associates were joined by a host of other doctors to build medical missions around the world one of which became a medical college and later a medical school associated with the University of Nanjing graduating 8,000 doctors a year from a student body in excess of 50,000. The overall impact of these medical missions and teams over the last 125 years has been enormous.

Our primary mandate now is to raise funds to assist in the very new medical research both here and abroad and to build a medical clinic and training center here in Ontario, Canada dedicated to and to continue with the important work of Dr. Lionel A. Macklin who specialized in paediatric reconstructive surgery.

In terms of cancer research and treatment and with the very recent clinical successes in trials with translational therapy of white cells taken from the patients body conjoined and modified with stem cells, these "translational cells" were injected back into the body to become hunter killers of all cancer cells; the time has come to bring this into the field of paediatrics. The clinical studies have shown results far in advance of what was expected. As result 70% of cancer patients to date even with stage four cancer showed a total [100%] remission of all cancer cells and related tumours, and 30% with a 70% remission with one month. Clinical studies showed no side affects at all. Now is the time to end surgery, and ectomies.
Now is also the time to stop the very olde and out of date processes of radiology and chemotherapy which practically guarantee a 20% chance that cancer will return.

Our secondary focus, also non-invasive, for this new team at the Macklin Medical Mission will be in the new and fascinating field of non-invasive micro-nuclear laser oncology leading the eradication of cancer cell nuclei already formed within the body’s organs and to eliminate the growth of new cancer cells identified and mapped by spectrum based cellular dyes. To narrow our focus we will be dealing especially with those cancer cells within the pancreas, the liver, the prostate and uterine walls. The use of micro-nuclear laser in combination with cellular dyes which will have the ability to change colour based on the process of necrosis of the cancer cell from this treatment and the rate at which the laser destroys the nuclei of the cancer cell.

In this regards it will be necessary to develop spectral based lasers each with their own unique ability to penetrate deeper into the structural mass of the body’s larger internal organs. Currently this range of treatment is limited to slightly more than 1 inch or 2½ centimetres without having to dissect the organ itself. As a first step then we will specialize in paediatric research and care field for the applied application of micro-nuclear lasers and the organ tissue to be dealt which is smaller in infants and children.

Patients will be brought to the new Macklin Medical Mission clinic for treatment on three floors of the west wing with attending physicians and researchers and general offices on the three adjoining floors of the east wing. This new Macklin Medical Mission medical center will be built once we have reach our financial goal of raising $23 million in terms of funds raised and pledges made.

We sincerely hope that you, and many others like you, will join in with us in these two important and critical new fields of paediatric medicine in cancer research, and in the creation of the new Dr. Lionel A. Macklin clinic and research center. Thousands of children are dying each and every day from the ravages of cancer in its many and varied forms. We now have the answer. Lets use it.

Its time we hand a final death sentence to cancer cells the same sentence cancer cells have been handing to our children as long as mankind has walked this earth. Our children deserve a life free of the ravages of cancer to a beautiful life and free even of the threat of cancer. I am sure you will agree. You only have to visit a cancer clinic in a hospital and see parents in total horror watch as their children die in front of them to know that you can not stand by – so please say yes and help us help them.

· No more Radiology
· No more Chemotherapy
· No more Barium treatments
· No more surgery
· No more related side tissue damage
· Breast and Ovarian cancer as a major threat to women is history
· Prostate and Testicular cancer as a major threat to men is history
· The terror of chronic leukemia is history

While cancer will remain as an illness, it too like the common cold is history as we speak. With the Macklin Medical Mission we can bring this cancer treatment to one and all, both children and adults. Please help us, as we all know someone who is affected by this scourge, is dying or has died of cancer. While this has come to late for so many, we need to finish the job.

One final note and that is that both Radiology and Chemotherapy as a form of cancer treatment that the side-affects are so abrasive to the human body that these orwellian treatments are responsible for a 20% chance for all cancer survivors of experiencing a second form of cancer within one year after remission of the first cancer.

The longer it takes, the longer we will watch and read about children dying in the arms of their parents.

We, at the Macklin Medical Mission, the oldest medical mission in the world, ask for your financial assistance to support our expanding efforts in this exciting new and highly successful field of white blood cells combined with T-Cell oncology research supported by the Nancy-Griffon Foundation Inc of Canada.
So, donate, support and invest in our cancer research – save a life.

Thank you.

Eric J. Macklin B.Com., FICB, FCSI, FMA, UE
Macklin Medical Mission  [Est. 1886]
Chairman
The Nancy-Griffon Foundation [Est. 1976]
Canada
www.nancygriffonfund.com

Friday, September 2, 2011

Macklin Medical Mission - Childrens Oncology Center (COG)

The Macklin Medical Mission
Center for Oncology Research and Treatment
Executive Summary

The Macklin Medical Mission is part of the Nancy-Griffon Foundation dedicated to the medical health and welfare of people. Over the years we have been involved in developing the funding and assistance for missions of medical specialists in the field of paediatrics and their staff and personnel around the world ever since the spring of 1885.

For the most part these team of specialist and generalist have been involved in reconstructive plastic surgery for the eyes, ears, nose and throat and in some cases rhinoplasty for cleft palates. Initially the latter came out of the work of many of our specialist as the result of war injuries, from the Crimean War to both the First and Second World Wars again specializing in injuries to the skull structure as well as those that evolved from birth defects later on.

From the early work led by Dr. William E. Macklin at the Nanking Medical Mission in Nanking China, later Nanjing up to the period of General Chiang Kai-Shek in the mid to late 1880’s to the late 1930’s to Dr. Alfred H. Macklin at the King George V hospital in Dublin Ireland. Both of these two famous Canadian doctors were later joined by Dr. Christine S. Macklin, one of the first women doctors to graduate from the University of Toronto and Dr. Daisy M. Macklin, both of who joined the Toronto Women’s Hospital. Dr. Bertrand Chapman’s work in New Delhi India was another medical mission supported by the Macklin Foundation.

Over the last 125 years Macklin doctors and their associates were joined by a host of other doctors to build medical missions around the world one of which became a medical college and later a medical school associated with the University of Nanjing graduating 8,000 doctors a year from a student body in excess of 50,000. The overall impact of these medical missions and teams over the last 125 years has been enormous.

Our primary mandate now is to raise funds to assist in the very new medical research both here and abroad and to build a medical clinic and training center here in Ontario, Canada dedicated to and to continue with the important work of Dr. Lionel A. Macklin who specialized in paediatric reconstructive surgery.

In terms of cancer research and treatment and with the very recent clinical successes in trials with translational therapy of white cells taken from the patients body conjoined and modified with stem cells, these "translational cells" were injected back into the body to become hunter killers of all cancer cells; the time has come to bring this into the field of paediatrics. The clinical studies have shown results far in advance of what was expected. As result 70% of cancer patients to date even with stage four cancer showed a total [100%] remission of all cancer cells and related tumours, and 30% with a 70% remission with one month. Clinical studies showed no side affects at all. Now is the time to end surgery, and ectomies.
Now is also the time to stop the very olde and out of date processes of radiology and chemotherapy which practically guarantee a 20% chance that cancer will return.

Our secondary focus, also non-invasive, for this new team at the Macklin Medical Mission will be in the new and fascinating field of non-invasive micro-nuclear laser oncology leading the eradication of cancer cell nuclei already formed within the body’s organs and to eliminate the growth of new cancer cells identified and mapped by spectrum based cellular dyes. To narrow our focus we will be dealing especially with those cancer cells within the pancreas, the liver, the prostate and uterine walls. The use of micro-nuclear laser in combination with cellular dyes which will have the ability to change colour based on the process of necrosis of the cancer cell from this treatment and the rate at which the laser destroys the nuclei of the cancer cell.

In this regards it will be necessary to develop spectral based lasers each with their own unique ability to penetrate deeper into the structural mass of the body’s larger internal organs. Currently this range of treatment is limited to slightly more than 1 inch or 2½ centimetres without having to dissect the organ itself. As a first step then we will specialize in paediatric research and care field for the applied application of micro-nuclear lasers and the organ tissue to be dealt which is smaller in infants and children.

Patients will be brought to the new Macklin Medical Mission clinic for treatment on three floors of the west wing with attending physicians and researchers and general offices on the three adjoining floors of the east wing. This new Macklin Medical Mission medical center will be built once we have reach our financial goal of raising $23 million in terms of funds raised and pledges made.

We sincerely hope that you, and many others like you, will join in with us in these two important and critical new fields of paediatric medicine in cancer research, and in the creation of the new Dr. Lionel A. Macklin clinic and research center. Thousands of children are dying each and every day from the ravages of cancer in its many and varied forms. We now have the answer. Lets use it.

Its time we hand a final death sentence to cancer cells the same sentence cancer cells have been handing to our children as long as mankind has walked this earth. Our children deserve a life free of the ravages of cancer to a beautiful life and free even of the threat of cancer. I am sure you will agree. You only have to visit a cancer clinic in a hospital and see parents in total horror watch as their children die in front of them to know that you can not stand by – so please say yes and help us help them.

· No more Radiology
· No more Chemotherapy
· No more Barium treatments
· No more surgery
· No more related side tissue damage
· Breast and Ovarian cancer as a major threat to women is history
· Prostate and Testicular cancer as a major threat to men is history
· The terror of chronic leukemia is history

While cancer will remain as an illness, it too like the common cold is history as we speak. With the Macklin Medical Mission we can bring this cancer treatment to one and all, both children and adults. Please help us, as we all know someone who is affected by this scourge, is dying or has died of cancer. While this has come to late for so many, we need to finish the job.

One final note and that is that both Radiology and Chemotherapy as a form of cancer treatment that the side-affects are so abrasive to the human body that these orwellian treatments are responsible for a 20% chance for all cancer survivors of experiencing a second form of cancer within one year after remission of the first cancer.

The longer it takes, the longer we will watch and read about children dying in the arms of their parents.

We, at the Macklin Medical Mission, the oldest medical mission in the world, ask for your financial assistance to support our expanding efforts in this exciting new and highly successful field of white blood cells combined with T-Cell oncology research supported by the Nancy-Griffon Foundation Inc of Canada.
So, donate, support and invest in our cancer research – save a life.

Thank you.

Eric J. Macklin B.Com., FICB, FCSI, FMA, UE
Macklin Medical Mission [Est 1886]
Chairman
The Nancy-Griffon Foundation Inc
Canada